Alaunos terminates key license with Precigen, pivots to oral obesity program; cash runway into Q1 2025

Alaunos Therapeutics, Inc.

Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.
Continues prosecuting TCR IP targeting KRAS, TP53, EGFR mutations and hunTR discovery platform.
Exploring strategic alternatives including acquisition, merger, reverse merger, or sale of assets.
Progressing internally developed small molecule oral obesity program; CMDO engaged for API manufacturing.
Cash runway extended into Q1 2025 via overhead reductions; in vitro testing planned Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.